Objectives  To investigate the status of infectious disease treatment in maintenance hemodialysis (MHD) patients with blood-borne infectious diseases.  Methods  The treatment data of infectious disease in MHD patients with hepatitis B virus (HBV), hepatitis C virus(HCV), human immunodeficiency virus (HIV), or  treponema pallidum (TP) infection in Beijing Ditan Hospital by August 2022 were collected. And the data of viral load or tolulized red unheated serum test (TRUST) were summarized.  Results  A total of 55 patients were enrolled, including 40 males (72.7%). The average age was 57.4 (±11.1) years. There were 27 patients with HBV infection. 16 (59.26%) patients have received anti-HBV treatment, and 9 (33.33%) patients with HBV infection have serum HBV-DNA higher than the detection limit. There were 9 patients with HCV infection, and 6 (66.67%) patients had received or were receiving anti-HCV treatment. Serum HCV-RNA was not detected in all patients with HCV infection. There were 21 patients with TP infection, including 2 patients with HBV co-infection and 2 patients with HIV co-infection. TRUST turned negative in 2 patients without any treatment, and the remaining 19 (90.48%) patients had been treated with penicillin, and 5 (23.81%) patients had high titer of TRUST. There were 2 HIV-infected patients, all of whom had received antiviral treatment(ART), and their serum HIV-RNA could not be detected. One of them had severe drug-induced hepatitis after the initial ART.  Conclusions  The treatment of infectious diseases among MHD patients with blood-borne infectious diseases needs to be further optimized. Multi-disciplinary communication and cooperation are needed to take safe and effective measures to minimize the infectivity of blood.